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Abstract  
BACKGROUND: Non-melanoma skin cancer (NMSC) is the most common malignancy in humans. Targeted 
therapy with monoclonal antibody cetuximab is an option in case of advanced tumor or metastasis. 
AIM: We present and update of the use of cetuximab in NMSC searching PUBMED 2011-2017. 
METHODS: The monoclonal antibody cetuximab against epidermal growth factor receptor (EGFR) has been 
investigated for its use in NMSC during the years 2011 to 2017 by a PUBMED research using the following items: 
“Non-melanoma skin cancer AND cetuximab,” “cutaneous squamous cell carcinoma AND cetuximab,” and “basal 
cell carcinoma AND cetuximab”, and “cetuximab AND skin toxicity”. Available data were analyzed including case 
reports.  
RESULTS: Current evidence of cetuximab efficacy in NMSC was mainly obtained in cutaneous SCC and to a 
lesser extend in BCC. Response rates vary for neoadjuvant, adjuvant, mono- and combined therapy with 
cetuximab. Management of cutaneous toxicities is necessary. Guidelines are available.  
CONCLUSIONS: Cetuximab is an option for recurrent or advanced NMSC of the skin. It seems to be justified 
particularly in very high-risk tumors. There is a need for phase III trials. 
 
 
 
 
 
Introduction 
 
Non-melanoma skin cancer (NMSC) is the 
most common malignancy in humans, with basal cell 
carcinoma (BCC) and cutaneous squamous cell 
carcinoma (cSCC) as the dominant tumor types [1]. 
As major risk factors the following findings could be 
identified: age ≥ 50 years of life, Fitzpatrick’s 
phototype I or II, and increased chronic exposure to 
natural or artificial ultraviolet (UV) irradiation. Other 
known risk factors include immunosuppression, solid 
organ transplantation, and use of tanning beds 
[1][2][3][4][5][6]. 
Logically, the reduction of UV-exposure 
seems the major goal in primary prevention [1]. The 
three pillars of current treatment for localized disease 
are surgery with wide excision, Mohs surgery for 
recurrent tumors or special localizations such as the 
face, and radiotherapy [1].  
The role of chemotherapy and targeted 
therapy in NMSC seems to be confined to advanced 
cases, where surgery has become impossible or is 
contraindicated, and to metastatic disease 
[8][9][10][11][12]. 
Cetuximab is a chimeric monoclonal antibody 
against epidermal growth factor receptor (EGFR) and 
had been FDA-approved for head and neck SCC in 
conjunction with radiotherapy [12].  
We present and update of the use of 
cetuximab in NMSC searching PUBMED 2011-2017. 
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BCC 
 
BCC is the most common human cancer. 
Age-adjusted BCC incidence (cases per 100,000 
person-years) was 360.0 in men and 292.9 in women 
in a recent population-based study in Olsmedt county, 
Missouri [13]. In contrast to cSCC, BCC does not 
increase cancer-related mortality [14]. BCC develops 
as a result of the interplay between ultraviolet 
radiation (UVR) and genotype with somatic mutations 
(Smoothed) and germline mutations/polymorphisms. 
The role of UVR exposure and BCC is not as clear as 
in cSCC [15]. 
Prognostic factors of BCCs are tumor size, 
histological subtype, tumor location, margins, and 
recurrence. The first line treatment of BCC is wide 
excision or Mohs surgery dependent on the site of 
tumor growth. In relapsed tumors, Mohs surgery 
provides a better outcome with a lower recurrence 
rate. Radiotherapy is an alternative for patients, who 
refuse surgery or where surgery is contraindicated. 
For advanced BCC, Smoothened (SMO) inhibitors 
vismodegib and sonidegib have been FDA approved 
[8][9].  
 
 
Cutaneous SCC 
 
Cutaneous SCC (cSCC) is the second most 
common NMSC. The age-adjusted cSCC incidence 
(cases per 100,000 person-years) has been 
calculated as high as 207.5 for men and 128.8 for 
women in Olmsted country [13]. The rate of 
metastasis has been estimated between 1.9 to 2.6%. 
Risk factors for metastatic spread are the maximum 
diameter, poor histological differentiation and 
particular anatomical localizations such as lip, cheek, 
and ear [16]. 
The risk of recurrence, metastases, and 
mortality can be further stratified. High-risk and very 
high-risk tumors are the possible indication for the use 
of cetuximab. 
High-risk tumors (HRSCC) are characterized 
by localization in the head-and-neck region, maximum 
diameter of more than 2 cm, invasion into the 
subcutaneous adipose tissue, poor differentiation, 
recurrence or occurrence in a previously irradiated 
area, and immunosuppression [16]. 
Very high-risk SCC (VHRSCC) include tumors 
with perineural, lympho-vascular, parotid, 
cartilaginous or bony invasion, in-transit, regional or 
distant metastases [17]. 
 
 
Studies of cetuximab in cutaneous SCC 
2011-17 
 
In 2011, the first phase II trial included 36 
patients with SCC. Disease control was obtained in 
69% after 6 weeks of treatment. Patients received a 
400 mg/m
2
 loading dose followed by 250 mg/m
2
 
weekly for at least 6 weeks with 48 weeks follow-up. 
In this study, three related serious adverse events 
were observed - two grade 4 infusion reactions and 
one grade 3 interstitial pneumonitis. Grade 1 to 2 
acne-like rash occurred in 78% of patients and was 
associated with prolonged PFS [18].  
 
Table 1: Results of cetuximab therapy in cSCC 2011-2017 (disease-free survival – DFS, overall survival – OAS, complete response 
– CR, partial response – PR, stable disease – SD, progressive disease – PD) 
_________________________________________________________________________________________
No.  Metastases  Best response  Outcome   Remarks   Reference 
36 lymph node  2 x CR    1 x at 6 months  in part with surgery  [18] 
   8 x PR      phase II trial 
   15 x SD 
   6 x PD 
   5 x not assessable 
1 lymph node  CR after 6 weeks  DFS 7 months  1
st
 line   [19] 
1 satellites  CR   > 6 months   plus volumetric modulated  
arc-radiotherapy   [20] 
8 -  3 x CR   3- >21 months  6 x with radiotherapy  [21] 
   2 x PR   6-18 months 
   1 x PD 
4 2 x lymph node 3 x CR   1 x relapse after 6 months,     [22] 
      median disease-free survival     
      20.5 months 
1 lung, pleura, lymph PR after 6 months  -   cetuximab plus paclitaxel  [23] 
 nodes            
3 -  1 x CR after 16 weeks  DFS 16 months     [24] 
   2 x PR   PR for 17 and 18 months 
   1 x PR   died from other reasons 
6 -  3 x CR   median 3 years  in combination with surgery [17] 
   2 x PD      VHRSCC 
   1 x intolerance       
17 bone or visceral 4 x PR   -   penile & scrotal,  [25] 
         cetuximab alone or 
         with cisplatin 
6 all metastatic  67% disease control  mean overall survival 25 ± 16.2    [26] 
   at 4 to 8 weeks  months 
1  -  CR   -      [27] 
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There have been a number of retrospective 
case series and case reports been published since 
then (Table 1). Cetuximab has been used as 1
st
 – 3
rd
 
line therapy, alone or in combination with surgery, 
radiotherapy or chemotherapy [17][18][19][20][21][22] 
[23][24][25][26][27].   
 
 
Cetuximab in advanced BCC 2011-2017 
 
Cetuximab has also been used in patients 
with advanced BCC [11]. The safety profile is not 
different from SCC patients. However, Karapurakal et 
al. (2015) used a lower starting dosage of 125 mg/m
2
 
increased to 250 mg/m
2
 or 300 mg/m
2
. Their dosages 
varied from 125 mg/m
2
 once a month to 300 mg/m
2
 
once a week. The authors did not explain the reason 
for these dose variations. Two patients achieved a 
CR, the other 2 had a PR. During a median follow-up 
of 12 months overall survival was 100%. Mean 
disease-free survival was one month. Three of their 
four patients suffered from Gorlin-Goltz syndrome 
[22]. 
 
 
Management of adverse effects 
 
Skin toxicity is the most common adverse 
effects of cetuximab. Treatment is based on skin 
moisturizers and sunscreens [28]. In a retrospective 
trial on gastrointestinal cancer patients, prophylactic 
and reactive treatment for acne-like rash was equally 
effective [29]. 
Treatment of the papulopustular rash includes 
topical use of erythromycin or metronidazole for mild 
cases, and systemic tetracyclines or retinoids for skin 
toxicities grade ≥2 with temporary interruption of 
cetuximab therapy [30]. The incidence of skin toxicity 
seems to be lower in smokers but the incidence of 
anorexia is higher compared to non-smokers [31]. 
Topical vitamin K3 (menadione) is not 
effective in the prevention of cutaneous toxicity nor 
does it change the expression of EGFR in skin [32]. 
In conclusion, there are increasingly more 
data available on the use of targeted therapy in 
advanced NMSC although controlled prospective, 
randomized, placebo-controlled phase III trials are still 
missing. From the available data, cetuximab seems to 
be effective as monotherapy after surgery. The safety 
profile is not different from approved indications such 
as advanced colorectal and head-and-neck cancer. In 
contrast to hedgehog inhibitor vismodegib approved 
for advanced BCC, second cSCC have not been 
observed with cetuximab therapy of NMSC 
[33][34][35][36]. 
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